{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:38:04Z","timestamp":1792255084892,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ygyno.2017.02.040","type":"journal-article","created":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T08:01:18Z","timestamp":1489132878000},"page":"291-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology\/Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"145","author":[{"given":"Janet S.","family":"Rader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Beumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Lankes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris Mangiaracina","family":"Benbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Trimble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tate Thigpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary E.","family":"Zuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Charles A.","family":"Leath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick M.","family":"Spirtos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Byron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal H.","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashikant","family":"Lele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ygyno.2017.02.040_bb0005","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.02.040_bb0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00404-013-2955-0","article-title":"Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysis","volume":"289","author":"Jin","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jnci\/86.7.539","article-title":"Enhancement of regression of CIN II with topically applied all-trans-retinoic acid: a randomized trial","volume":"86","author":"Meyskens","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1006\/gyno.1997.4697","article-title":"Effects of B-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection","volume":"65","author":"Romney","year":"1997","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0025","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1078-0432.390.11.1","article-title":"Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3","volume":"11","author":"Vlastos","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/gyno.2000.5847","article-title":"Placebo-controlled trial of indole-3-carbinol in the treatment of CIN","volume":"78","author":"Bell","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2009.06.042","article-title":"Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study","volume":"115","author":"Van Pachterbeke","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0040","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/AOG.0b013e31825bc6e8","article-title":"Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial","volume":"120","author":"Grimm","year":"2012","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2006.03.036","article-title":"A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia","volume":"103","author":"Farley","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0050","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1200\/JCO.2002.20.4.973","article-title":"Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients","volume":"20","author":"Ferrandina","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0055","first-page":"429","article-title":"Cyclooxygenas-2 is overexpressed in human cervical cancer","volume":"7","author":"Kulkarni","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2017.02.040_bb0065","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa061355","article-title":"Celecoxib for the prevention of sporadic colorectal adenomas","volume":"355","author":"Bertagnolli","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0070","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/jnci\/djq442","article-title":"Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial","volume":"102","author":"Elmets","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0075","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1002\/cncr.28953","article-title":"Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients","volume":"120","author":"Derosa","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.02.040_bb0080","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/0008-5472.CAN-03-1945","article-title":"Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity","volume":"64","author":"Wei","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3892\/mmr.2014.2730","article-title":"Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor","volume":"11","author":"Xu","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/0717-6287-47-27","article-title":"Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy","volume":"47","author":"Rosas","year":"2014","journal-title":"Biol. Res."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0095","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.3892\/or.2014.3093","article-title":"Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN\/PI3K\/Akt\/HIF-1 pathway in an H(2)(2) murine hepatocarcinoma model","volume":"31","author":"Sui","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0100","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.oraloncology.2011.05.009","article-title":"Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer","volume":"47","author":"Halamka","year":"2011","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0105","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/1471-2407-8-218","article-title":"Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells","volume":"8","author":"Zhu","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2017.02.040_bb0110","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1940-6207.CAPR-11-0078","article-title":"Lung cancer chemoprevention with celecoxib in former smokers","volume":"4","author":"Mao","year":"2011","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.ygyno.2017.02.040_bb0115","doi-asserted-by":"crossref","first-page":"7113","DOI":"10.1158\/0008-5472.CAN-07-0260","article-title":"Profiling Microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates","volume":"67","author":"Gius","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0120","first-page":"1294","article-title":"Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice","volume":"57","author":"Smith-McCune","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0125","first-page":"800","article-title":"Demonstration and characterization of the angiogenic properties of cervical dysplasia","volume":"54","author":"Smith-McCune","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0130","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ygyno.2008.04.038","article-title":"Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease","volume":"110","author":"Hammes","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0135","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/jnci\/89.16.1212","article-title":"Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia","volume":"89","author":"Obermair","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0140","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejogrb.2005.08.019","article-title":"The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II\u2013III A phase II trial","volume":"125","author":"Hefler","year":"2006","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004121.pub3","article-title":"Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia","volume":"4","author":"Grabosch","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0150","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1158\/1055-9965.EPI-14-3-EDA","article-title":"What happened to the coxibs on the way to the cardiologist?","volume":"14","author":"Alberts","year":"2005","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0155","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2165\/00003088-200342030-00003","article-title":"Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib","volume":"42","author":"Brenner","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/1055-9965.EPI-03-0163","article-title":"Effects of a high-selenium yeast supplement on celecoxib plasma levels: a randomized phase II trial","volume":"13","author":"Frank","year":"2004","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0165","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2407-8-49","article-title":"Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women","volume":"8","author":"Sauter","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2017.02.040_bb0170","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1158\/1940-6207.CAPR-09-0233","article-title":"Biological activity of celecoxib in the bronchial epithelium of current and former smokers","volume":"3","author":"Kim","year":"2010","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.ygyno.2017.02.040_bb0175","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of Celecoxib, a cyclooxygenase-2 inhibitor in familial adenomatous polyposis","volume":"342","author":"Steinbach","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.02.040_bb0180","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1158\/1940-6207.CAPR-07-0003","article-title":"A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions","volume":"1","author":"Wirth","year":"2008","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.ygyno.2017.02.040_bb0190","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PGP.0b013e31826916c7","article-title":"The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology","volume":"32","author":"Darragh","year":"2013","journal-title":"Int. J. Gynecol. Pathol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817301610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817301610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T21:17:34Z","timestamp":1658783854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817301610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0090825817301610"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.040","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology\/Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.02.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}